Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Cancer Type/Condition:  Pheochromocytoma
Stage/Subtype:  recurrent pheochromocytoma
Trial Type:  Treatment
Trial Status:  Active
Results 1-16 of 16 for your search:
Start Over
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CSOM230B2412, NCT01794793
Randomized Phase III of PRRT Versus Interferon
Phase: Phase III
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: IJBMNCASTOR, 2012-005545-20, NCT01860742
Interleukin 13 PE for Adults With Advanced Cancers
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130046, 13-C-0046, NCT01766635
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 1
Sponsor: NCI
Protocol IDs: 04-148, MSKCC-04148, NCT00107289
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SNIPP, NCT00843037
A Study Evaluating Ultratrace Iobenguane I 131 (MIBG) in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MIP-IB12B, NCT00874614
DOTA-TOC in Metastasized Neuroendocrine Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MAW002, NCT00978211
Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: EudraCT 2006-004748-22, NCT01203306
177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 78,256, NCT01237457
First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: IGR2010/1715, 2010-024621-20, MSI/A110356-31, NCT01371201
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 140001, 14-C-0001, NCT01967576
Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 2 to 25
Sponsor: NCI, Other
Protocol IDs: CDR0000257582, UIHC-200008086, NCI-V02-1710, 200008086, NCT00049023
Phase Ib Study of Sulfatinib in Treating Advanced Neuroendocrine Tumors
Phase: Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2014-012-00CH1, NCT02267967
Best Therapy for Patients With Neuroendocrine Tumors
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: ZBB-NET-1, NCT00815620
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Phase: No phase specified
Type: Supportive care, Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: 2012LS107, NCT01850888
Cabozantinib for Malignant Pheochromocytoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2014-0081, NCI-2014-02607, NCT02302833
Start Over